Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Joseph Larosa Sells 4,466 Shares of Company Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Joseph Larosa sold 4,466 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the transaction, the executive vice president owned 38,906 shares of the company’s stock, valued at approximately $37,563,353.94. This trade represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Regeneron Pharmaceuticals Stock Down 4.4%

NASDAQ REGN opened at $930.67 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35. The stock has a market cap of $95.82 billion, a PE ratio of 20.55, a PEG ratio of 1.45 and a beta of 0.10. The firm has a 50-day simple moving average of $800.69 and a 200 day simple moving average of $741.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm’s revenue was up 36.3% on a year-over-year basis. During the same period in the previous year, the business earned $11.83 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 51.64 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be issued a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.30%.

Analyst Ratings Changes

REGN has been the topic of a number of analyst reports. Bank of America increased their price target on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday. Jefferies Financial Group upped their target price on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a report on Monday. Canaccord Genuity Group lifted their price target on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, Robert W. Baird upped their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the company a “neutral” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $898.97.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Lido Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 26.0% in the third quarter. Lido Advisors LLC now owns 14,677 shares of the biopharmaceutical company’s stock worth $11,129,000 after acquiring an additional 3,030 shares during the period. Cornerstone Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $254,000. Csenge Advisory Group purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $237,000. Kestra Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.4% in the third quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 16 shares during the period. Finally, AlphaCore Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 133.5% in the 3rd quarter. AlphaCore Capital LLC now owns 1,602 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 916 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.